DEVELOPMENT OF ANTICONVULSANT OSTEOMALACIA IN EPILEPTIC PATIENTS ON PHENYTOIN TREATMENT

Authors

  • P. Rødbro,

    1. Glostrup Hospital, Departments of Clinical Physiology and Clinical Chemistry, Department of Neurology and Aalborg Sygehus Syd, Department of Clinical Physiology, Denmark
    Search for more papers by this author
  • C. Christiansen,

    Corresponding author
    1. Glostrup Hospital, Departments of Clinical Physiology and Clinical Chemistry, Department of Neurology and Aalborg Sygehus Syd, Department of Clinical Physiology, Denmark
    Search for more papers by this author
  • M. Lund

    1. Glostrup Hospital, Departments of Clinical Physiology and Clinical Chemistry, Department of Neurology and Aalborg Sygehus Syd, Department of Clinical Physiology, Denmark
    Search for more papers by this author

C. Christiansen, M.D. Department of Clinical Chemistry Glnstrup Hospital 2600 Glostrnp Denmark

ABSTRACT

In 151 epileptic patients, who had been treated with phenytoin for from 3 months to 31 years, the three indices of anticonvulsant osteomalacia: Serum calcium, serum alkaline phosphatase, and bone mineral content were studied to find the relation between the pathological changes and the duration of phenytoin treatment. The results indicate that anticonvulsant osteomalacia sets in quite early after institution of phenytoin treatment, and is kept at a constant level thereafter. If epileptics should have prophylactic vitamin D treatment, the extra supply of vitamin D probably should he given from the beginning of the anticonvulsant therapy.

Ancillary